New York, United States
EVQLV is a US-based startup that is revolutionizing the design and development of therapeutic antibodies by leveraging advances in computation. Established in 2019, the company works with partners at the discovery stage to accelerate the speed of antibody discovery. Its services extend to supporting the optimization of antibody candidates, developing assets that expand IP protection, and designing next-generation and innovative immunotherapies for collaborators with preclinical, clinical, or commercial assets. EVQLV's operations are characterized by accelerated speed and scale, made feasible by leveraging computational tools that learn from massive and diverse datasets.
Having been backed by Endeavor Miami in its most recent investment round, EVQLV operates within the intersecting industries of AI, Biotechnology, Life Sciences, Pharmaceutical, and Machine Learning. This strategic positioning underscores the company's commitment to capitalizing on the potential for technological disruption and innovation in these sectors, which are poised for significant growth and development.
